Unicycive Therapeutics Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Unicycive Therapeutics Inc's ROA in the second quarter of 2026?
Unicycive Therapeutics Inc recorded a cumulative net loss of $-35 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -59.55%.

However, within the Healthcare sector 637 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 4051 to 4345.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	140.14 %	127.76 %	55.13 %	34.27 %	-32.9 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-35	-40	-27	-28	-26
Return On Assets (TTM)	-59.55 %	-82.13 %	-67.01 %	-77.93 %	-79.99 %
UNCY's Total Ranking	# 4345	# 4051	# 5144	# 4488	# 4605
Total Assets (TTM) in million	72	64	49	52	30
Seq. Total Assets Change	13.16 %	29.56 %	-5.15 %	72.68 %	7.33 %
Seq. Net Income Change	-	-	-	-	-

UNCY's 5 Years Annual ROA >> Back to UNCY Management Effectiveness >> Compare UNCY ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 288
Sector	# 638
Overall	# 4126

Return On Assets Statistics
High	Average	Low
-42.71 %	-109 %	-219.54 %
(Mar 31 2025)		(Mar 31 2023)

Financial Statements
Unicycive Therapeutics Inc's Assets	$ 72 million	UNCY's Balance sheet
Unicycive Therapeutics Inc's Income	$ -2 million	Quarterly UNCY's Income Statement
UNCY's Income by Division		See UNCY's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	55.13 %	-20.63 %	1315.79 %	-84.97 %	-
Total Assets in million	49	32	40	3	19
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-27	-37	-31	-18	-10
Annual Return On Assets	-54.05 %	-115.98 %	-76.56 %	-640.81 %	-53.44 %

UNCY's 5 Years Annual ROA >> Back to UNCY Management Effectiveness >> Compare UNCY ROA to its Competitors

More Return On Assets Ratios
UNCY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
UNCY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for UNCY's Competitors
Subscribers only: Roa for Unicycive Therapeutics Inc's Suppliers
Subscribers only: Return On Assets for UNCY's Customers

You may also want to know
UNCY's Roi	UNCY's Inventory Turnover Ratio	UNCY's Growth Rates	UNCY's Dividend Comparisons
	UNCY's Profitability Ratios	UNCY's Asset Turnover Ratio	UNCY's Dividend Growth
UNCY's Roe	UNCY's Valuation Ratios	UNCY's Financial Strength Ratios	UNCY's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:40:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.